Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,865
archived clinical trials in
Multiple Sclerosis

Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis Investigative Site
mi
from
Seattle, WA
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis Investigative Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Expiratory Muscle Training for Persons With Neurodegenerative Disease
Expiratory Muscle Training for Persons With Neurodegenerative Disease
Status: Enrolling
Updated:  10/10/2013
North Florida/South Georgia Veterans Health System
mi
from
Gainesville, FL
Expiratory Muscle Training for Persons With Neurodegenerative Disease
Expiratory Muscle Training for Persons With Neurodegenerative Disease
Status: Enrolling
Updated: 10/10/2013
North Florida/South Georgia Veterans Health System
mi
from
Gainesville, FL
Click here to add this to my saved trials
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  10/15/2013
Osmotica Study Site-138
mi
from
Cullman, AL
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 10/15/2013
Osmotica Study Site-138
mi
from
Cullman, AL
Click here to add this to my saved trials
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  10/15/2013
Osmotica Study Site-123
mi
from
Aurora, CO
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 10/15/2013
Osmotica Study Site-123
mi
from
Aurora, CO
Click here to add this to my saved trials
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  10/15/2013
Osmotica Study Site
mi
from
Bradenton, FL
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 10/15/2013
Osmotica Study Site
mi
from
Bradenton, FL
Click here to add this to my saved trials
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  10/15/2013
Osmotica Study Site-142
mi
from
Maitland, FL
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 10/15/2013
Osmotica Study Site-142
mi
from
Maitland, FL
Click here to add this to my saved trials
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  10/15/2013
Osmotica Study Site-119
mi
from
Ormond Beach, FL
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 10/15/2013
Osmotica Study Site-119
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  10/15/2013
Osmotica Study Site-120
mi
from
Pompano Beach, FL
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 10/15/2013
Osmotica Study Site-120
mi
from
Pompano Beach, FL
Click here to add this to my saved trials
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  10/15/2013
Osmotica Study Site-109
mi
from
Tampa, FL
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 10/15/2013
Osmotica Study Site-109
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  10/15/2013
Osmotica Study Site
mi
from
Northbrook, IL
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 10/15/2013
Osmotica Study Site
mi
from
Northbrook, IL
Click here to add this to my saved trials
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  10/15/2013
Osmotica Study Site-108
mi
from
Fort Wayne, IN
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 10/15/2013
Osmotica Study Site-108
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  10/15/2013
Osmotica Study Site
mi
from
Lenexa, KA
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 10/15/2013
Osmotica Study Site
mi
from
Lenexa, KA
Click here to add this to my saved trials
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  10/15/2013
Osmotica Study Site-124
mi
from
Baltimore, MD
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 10/15/2013
Osmotica Study Site-124
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  10/15/2013
Osmotica Study Site-136
mi
from
Springfield, MA
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 10/15/2013
Osmotica Study Site-136
mi
from
Springfield, MA
Click here to add this to my saved trials
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  10/15/2013
Osmotica Study Site
mi
from
Ann Arbor, MI
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 10/15/2013
Osmotica Study Site
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  10/15/2013
Osmotica Study Site
mi
from
Johnson City, NY
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 10/15/2013
Osmotica Study Site
mi
from
Johnson City, NY
Click here to add this to my saved trials
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  10/15/2013
Osmotica Study Site-125
mi
from
New York, NY
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 10/15/2013
Osmotica Study Site-125
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  10/15/2013
Osmotica Study Site-141
mi
from
New York, NY
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 10/15/2013
Osmotica Study Site-141
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  10/15/2013
Osmotica Study Site
mi
from
Charlotte, NC
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 10/15/2013
Osmotica Study Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  10/15/2013
Osmotica Study Site
mi
from
Cincinnati, OH
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 10/15/2013
Osmotica Study Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  10/15/2013
Osmotica Study Site
mi
from
Pittsburgh, PA
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 10/15/2013
Osmotica Study Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  10/15/2013
Osmotica Study Site
mi
from
San Antonio, TX
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 10/15/2013
Osmotica Study Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  10/15/2013
Osmotica Study Site-133
mi
from
Salt Lake City, UT
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 10/15/2013
Osmotica Study Site-133
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  10/15/2013
Osmotica Study Site-129
mi
from
Seattle, WA
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 10/15/2013
Osmotica Study Site-129
mi
from
Seattle, WA
Click here to add this to my saved trials
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated:  10/31/2013
Osmotica Study Site
mi
from
Gilbert, AZ
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated: 10/31/2013
Osmotica Study Site
mi
from
Gilbert, AZ
Click here to add this to my saved trials
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated:  10/31/2013
Osmotica Study Site-158
mi
from
Phoenix, AZ
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated: 10/31/2013
Osmotica Study Site-158
mi
from
Phoenix, AZ
Click here to add this to my saved trials
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated:  10/31/2013
Osmotica Study Site-165
mi
from
Pasadena, CA
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated: 10/31/2013
Osmotica Study Site-165
mi
from
Pasadena, CA
Click here to add this to my saved trials
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated:  10/31/2013
Osomtica Study Site-164
mi
from
Torrance, CA
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated: 10/31/2013
Osomtica Study Site-164
mi
from
Torrance, CA
Click here to add this to my saved trials
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated:  10/31/2013
Osmotica Study Site-164
mi
from
Torrance, CA
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated: 10/31/2013
Osmotica Study Site-164
mi
from
Torrance, CA
Click here to add this to my saved trials
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated:  10/31/2013
Osmotica Study Site
mi
from
Bradenton, FL
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated: 10/31/2013
Osmotica Study Site
mi
from
Bradenton, FL
Click here to add this to my saved trials
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated:  10/31/2013
Osmotica Study Site-120
mi
from
Pompano Beach, FL
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated: 10/31/2013
Osmotica Study Site-120
mi
from
Pompano Beach, FL
Click here to add this to my saved trials
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated:  10/31/2013
Osmotica Study Site-109
mi
from
Tampa, FL
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated: 10/31/2013
Osmotica Study Site-109
mi
from
Tampa, FL
Click here to add this to my saved trials
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated:  10/31/2013
Osmotica Study Site
mi
from
Northbrook, IL
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated: 10/31/2013
Osmotica Study Site
mi
from
Northbrook, IL
Click here to add this to my saved trials
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated:  10/31/2013
Osmotica Study Site
mi
from
Lenexa, KA
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated: 10/31/2013
Osmotica Study Site
mi
from
Lenexa, KA
Click here to add this to my saved trials
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated:  10/31/2013
Osmotica Study Site
mi
from
Ann Arbor, MI
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated: 10/31/2013
Osmotica Study Site
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated:  10/31/2013
Osmotica Study Site-161
mi
from
Plainview, NY
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated: 10/31/2013
Osmotica Study Site-161
mi
from
Plainview, NY
Click here to add this to my saved trials
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated:  10/31/2013
Osmotica Study Site-151
mi
from
Charlotte, NC
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated: 10/31/2013
Osmotica Study Site-151
mi
from
Charlotte, NC
Click here to add this to my saved trials
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated:  10/31/2013
Osmotica Study Site-155
mi
from
Raleigh, NC
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated: 10/31/2013
Osmotica Study Site-155
mi
from
Raleigh, NC
Click here to add this to my saved trials
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated:  10/31/2013
Osmotica Study Site-152
mi
from
Wilmington, NC
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated: 10/31/2013
Osmotica Study Site-152
mi
from
Wilmington, NC
Click here to add this to my saved trials
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated:  10/31/2013
Osmotica Study Site-156
mi
from
Dayton, OH
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated: 10/31/2013
Osmotica Study Site-156
mi
from
Dayton, OH
Click here to add this to my saved trials
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated:  10/31/2013
Osmotica Study Site-163
mi
from
Philadelphia, PA
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated: 10/31/2013
Osmotica Study Site-163
mi
from
Philadelphia, PA
Click here to add this to my saved trials
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated:  10/31/2013
Osmotica Study Site-162
mi
from
Franklin, TN
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated: 10/31/2013
Osmotica Study Site-162
mi
from
Franklin, TN
Click here to add this to my saved trials
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated:  10/31/2013
Osmotica Study Site
mi
from
San Antonio, TX
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated: 10/31/2013
Osmotica Study Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated:  10/31/2013
Osmotica Study Site-166
mi
from
Vienna, VA
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
Status: Enrolling
Updated: 10/31/2013
Osmotica Study Site-166
mi
from
Vienna, VA
Click here to add this to my saved trials
Correlation Between Relapses in Multiple Sclerosis (MS) and Vitamin D Intake
Correlation Between Relapses in Multiple Sclerosis (MS) and Vitamin D Intake
Status: Enrolling
Updated:  11/19/2013
OSF Saint Francis Medical Center
mi
from
Peoria, IL
Correlation Between Relapses in Multiple Sclerosis (MS) and Vitamin D Intake
Correlation Between Relapses in Multiple Sclerosis (MS) and Vitamin D Intake
Status: Enrolling
Updated: 11/19/2013
OSF Saint Francis Medical Center
mi
from
Peoria, IL
Click here to add this to my saved trials
FlexToBa for People With Multiple Sclerosis
Improving Functional Performance in Persons With MS Via Physical Activity DVD Intervention
Status: Enrolling
Updated:  11/20/2013
University of Illinois at Urbana-Champaign
mi
from
Urbana, IL
FlexToBa for People With Multiple Sclerosis
Improving Functional Performance in Persons With MS Via Physical Activity DVD Intervention
Status: Enrolling
Updated: 11/20/2013
University of Illinois at Urbana-Champaign
mi
from
Urbana, IL
Click here to add this to my saved trials
Comparison of the Efficacy and Mechanisms for MBCT and CT for Multiple Sclerosis (MS) Chronic Pain
The Efficacy and Mechanisms of Cognitive Therapy Compared to Mindfulness-Based Cognitive Therapy in Multiple Sclerosis (MS) Pain
Status: Enrolling
Updated:  12/9/2013
UW Medicine Multiple Sclerosis Center
mi
from
Seattle, WA
Comparison of the Efficacy and Mechanisms for MBCT and CT for Multiple Sclerosis (MS) Chronic Pain
The Efficacy and Mechanisms of Cognitive Therapy Compared to Mindfulness-Based Cognitive Therapy in Multiple Sclerosis (MS) Pain
Status: Enrolling
Updated: 12/9/2013
UW Medicine Multiple Sclerosis Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Testing the Efficacy of Self-Generation Treatment Protocol
Exploring the Effects of a Memory Intervention on Memory and Everyday Life Activities With Persons With MS
Status: Enrolling
Updated:  1/9/2014
Kessler Foundation
mi
from
West Orange, NJ
Testing the Efficacy of Self-Generation Treatment Protocol
Exploring the Effects of a Memory Intervention on Memory and Everyday Life Activities With Persons With MS
Status: Enrolling
Updated: 1/9/2014
Kessler Foundation
mi
from
West Orange, NJ
Click here to add this to my saved trials
Pilot Study of Free From Falls Program in Multiple Sclerosis
Pilot Study on the Effect of the Free From Falls Program on Falls in People With Multiple Sclerosis
Status: Enrolling
Updated:  1/13/2014
Oregon Health and Science University and Portland VA Medical Center
mi
from
Portland, OR
Pilot Study of Free From Falls Program in Multiple Sclerosis
Pilot Study on the Effect of the Free From Falls Program on Falls in People With Multiple Sclerosis
Status: Enrolling
Updated: 1/13/2014
Oregon Health and Science University and Portland VA Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis
Status: Enrolling
Updated:  1/30/2014
North Central Neurology Associates, PC
mi
from
Cullman, AL
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis
Status: Enrolling
Updated: 1/30/2014
North Central Neurology Associates, PC
mi
from
Cullman, AL
Click here to add this to my saved trials